For most of the twentieth century, small molecule drugs were the backbone of pharmaceutical treatment. A compound synthesised in a lab, manufactured at scale, packaged, and prescribed. The model worked — and still does — but it has always had a ceiling. There are conditions it can manage but not meaningfully alter. Diseases can slow but not stop. That ceiling is a big part of why the shift toward therapeutic biological products has been so significant, and why the pharma industry has been paying close attention.
Biologics aren’t a new idea, but what’s changed is how central they’ve become to treatment strategy across a growing number of disease areas — and what that means for manufacturers, developers, and brands operating in this space.
What Makes Biologics Different?
Unlike conventional drugs derived from chemical synthesis, therapeutic biological products are derived from living cells — whether bacterial, yeast, mammalian, or other biological sources. That origin is what gives them their power. They can be designed to interact with the body’s own mechanisms in highly specific ways — targeting a particular protein, modulating an immune response, or mimicking a molecule the body produces naturally.
That specificity is the point. A biologic developed for rheumatoid arthritis isn’t just reducing inflammation generally — it’s targeting the precise pathway driving that inflammation. For patients who haven’t responded to conventional therapeutic products, that precision can be the difference between managing a condition and actually living with it on better terms.
This is what has changed treatment outcomes in areas like oncology, autoimmune disease, rare genetic disorders, and metabolic conditions. Not incrementally, but in ways that were simply not possible a generation ago.
Why Demand Has Grown — and Keeps Growing?
A few things are happening simultaneously that explain the sustained demand for biologics.
The global burden of chronic and complex disease is increasing. Conditions like cancer, diabetes, inflammatory diseases, and neurological disorders are being diagnosed in larger numbers and in younger populations than before. These are exactly the disease areas where biologics have demonstrated the strongest clinical value — and where conventional small molecule treatments often fall short.
At the same time, the biosimilars market has made therapeutic biological products more financially accessible. As patents on originator biologics expire, biosimilar manufacturers have been able to bring comparable products to market at lower price points, which has expanded access without compromising on the clinical logic that made these molecules valuable in the first place.
There’s also a research dimension. As biological science has advanced — genomics, proteomics, cell biology — the ability to identify new biological targets and develop molecules against them has accelerated. The pipeline of therapeutic biological products in development globally is broader and deeper than it has ever been.
The Availability Question — and Where Digital Access Fits in
One shift worth noting is how procurement and information-seeking around therapeutic products has moved online. Pharma companies, hospital procurement teams, and healthcare distributors increasingly look for therapeutic products online — researching manufacturers, comparing specifications, evaluating regulatory credentials, and initiating supplier conversations digitally before any formal engagement happens.
This has raised the bar for manufacturers and CDMOs operating in this space. It’s no longer enough to have the right capabilities — those capabilities need to be visible, clearly communicated, and backed by the kind of regulatory and quality documentation that procurement teams can evaluate without a site visit.
What does this mean for the Industry?
For pharma companies and brands thinking about where biologics fit in their pipeline or portfolio, a few things are worth keeping in mind.
Manufacturing complexity is real. Biologics require a fundamentally different production environment than conventional drugs — specialised equipment, stringent process controls, cold chain management, and highly trained personnel. Choosing a development and manufacturing partner with genuine experience in this space matters more than it might for a standard formulation.
Regulatory pathways are also more involved. Whether you’re developing an originator biologic or a biosimilar, the evidence requirements are substantial. Working with a partner who understands that landscape — across markets — reduces risk considerably.
The commercial opportunity is there for those who are ready for it. Biologics are no longer an emerging category — they’re central to where serious pharma investment is going. And India, increasingly, is where a meaningful part of that manufacturing is happening.
